Page 2 - Pharma Sector

Strong US sales momentum may drive further gains for Zydus Lifesciences

Market share gains in the Indian market and margin expansion are other positives

Granules India ties up with Greenko Group for 'green' pharma zones

As a part of the partnership, Granules and Greenko ZeroC will develop and promote state-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh

Timely resolution of FDA action crucial to Indian pharma's US pipeline

Analysts say overall risks remain high for US generics business

Cough syrup deaths: Centre, UP team inspect pharma firm's Noida unit

Cough syrup maker linked to Uzbekistan deaths halts production; samples of Dok-1 Max sent for analysis

After Gambia, now Uzbekistan alleges Indian cold drug killed its children

Noida-based Marion Biotech's Dok-1 Max anti-cold medicine under scanner after the Central Asian nation blames it for 18 deaths

Bitter medicine for pharma regulation

The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape

Domestic, semi-regulated markets to drive pharmaceutical industry's growth

High raw material prices to put pressure on margins

CDSCO, states begin joint checks of drug-making units across India

Objective of drug regulation is to ensure safety, efficacy, and quality of drugs

WHO stands by action of issuing alert against Maiden Pharma cough syrup

Asserts that testing done in labs in Ghana and Switzerland confirmed excess levels of contaminated syrups that are "dangerous and should not be in any medicine, ever"

AstraZeneca Pharma India's MD resigns; appoints Sanjeev Panchal for 3 years

AstraZeneca Pharma India on Wednesday said Gagandeep Singh Bedi has resigned from the post of managing director. The drug firm said it has approved the appointment of Sanjeev Panchal as its managing director for a period of three years with effect from January 1, 2023. Panchal had joined AstraZeneca Pharma in February 2003 as Brand Associate and progressed through several positions in India, Indonesia, Asia Pacific and the international region, based in Singapore and the United Kingdom (UK), it said.

Torrent Pharma, Boehringer Ingelheim India to co-market diabetes drug

Torrent Pharmaceuticals on Wednesday said it has inked a pact with Boehringer Ingelheim India to co-market diabetes drug and its combinations in the country. The company has inked an agreement to jointly sell Cospiaq (Empagliflozin), Cospiaq Met (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin). Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. It is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. "I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and bolster our position as a leading player in these high growth segments within the Indian pharmaceutical market," Torrent Pharmaceuticals Director Aman Mehta said in a statement. Boehringer Ingelheim India Managing Direct

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Eyestem to start first trial in India to treat age-related blindness

The first nine patients that they will inject would be legally blind, as they have to prove safety first

Drug, medical services firm PharmEasy may lay off hundreds of employees

The company has a total workforce of about 1500

Podcast: Will Viatris deal inject fresh momentum into Biocon biz?

Sohini Das caught up with Biocon Biologics CEO Shreehas Tambe to know more about the deal and the company's future plans

Tax sops for craft paper, textile, pharma units in Madhya Pradesh

The Madhya Pradesh government is leaving no stone unturned to facilitate investment assistance to various sectors

Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA

The USFDA had imposed an import ban on the Halol plant in December 2015 too

Pharma logs 17% growth in Nov; anti-infective therapy drives market demand

Key antibiotic brands like Augmentin (GSK) and Clavam (Alkem) clocked 25 per cent and 29 percent growth, respectively, in November, the data showed

Innovator drugs maintain market hold even after patent expiry, shows data

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Biocon Biologics elevates Shreehas Tambe as managing director, CEO

Biocon Biologics on Monday said it has elevated Shreehas Tambe as Managing Director and CEO of the company with immediate effect. Tambe was Deputy CEO of Biocon Biologics, a subsidiary of Bengaluru-based Biocon. He takes over from Arun Chandavarkar, who will continue to serve as a non-executive, non-independent director on the Biocon Biologics board, the company said in a statement. Shreehas is taking on the responsibility of leading Biocon Biologics as MD & CEO at a time when the company is gearing up for global leadership in biosimilars with the closing of the Viatris acquisition, Biocon & Biocon Biologics Executive Chairperson Kiran Mazumdar-Shaw said. Shreehas will be aided by a highly experienced executive leadership team in building a future-ready, world leading biosimilars player and a well-recognised global brand that is committed to impacting global healthcare, she added. Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.